Browsing tag:


Regorafenib is a formidable treatment for colon cancer, and in late 2013 it has received another new approval for GIST in Japan and Europe. Known as the trade name Stivarga, Regorafenib was approved in both Japan and Europe for the treatment of gastrointestinal stromal tumors. The FDA approved Regorafenib two years ago and added the[…]

Read More

The Regorafenib tablet gains EU approval for the treatment of metastasized colorectal cancer (mCRC) in adults, whose disease has progressed even after treatment with standard drugs. Regorafenib was previously approved by the FDA in late May 2012 to treat patients with metastatic colorectal cancer. That initial approval of Regorafenib for unresectable colon cancer was based on the[…]

Read More

Bayer announced the Regorafenib FDA Approval on February 25, 2013. Known as the brand name Stivarga, Regorafenib is specifically for patients with gastrointestinal stromal tumor (GIST) that is unresectable.  Regorafenib is a last option treatment for patients with GIST who have metastatic cancer that is unresponsive to first line treatments approved by the FDA, like[…]

Read More

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service